TY - JOUR
T1 - A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate
AU - Patel, S. R.
AU - Kvols, L. K.
AU - Hahn, R. G.
AU - Windschitl, H.
AU - Levitt, R.
AU - Therneau, T.
PY - 1990/8/15
Y1 - 1990/8/15
N2 - The results of a randomized, multicenter, cooperative group trial evaluating hormonal therapy with either megestrol acetate or dexamethasone in advanced, hormonally refractory prostate cancer are reported. Three of 29 patients (∼10%) on the megestrol acetate arm experienced an objective response lasting 41, 84, and 202 days, respectively, whereas two of 29 patients (∼7%) on the dexamethasone arm achieved an objective response lasting 359 and 512 days, respectively. Twenty of 29 patients (∼69%) on the megestrol acetate arm had stable disease lasting for a median duration of 117 days, whereas 21 of 29 patients (72%) on the dexamethasone arm had stable disease for a median duration of 86 days. Median survival of all patients was 9 months from initiation of treatment. The median survival for patients on the megestrol acetate arm was 268 days compared to 246 days for patients on the dexamethasone arm (P = 0.2). Neither dexamethasone nor megestrol acetate would seem to be of substantive value in altering the progression of advanced, hormonally refractory prostate cancer.
AB - The results of a randomized, multicenter, cooperative group trial evaluating hormonal therapy with either megestrol acetate or dexamethasone in advanced, hormonally refractory prostate cancer are reported. Three of 29 patients (∼10%) on the megestrol acetate arm experienced an objective response lasting 41, 84, and 202 days, respectively, whereas two of 29 patients (∼7%) on the dexamethasone arm achieved an objective response lasting 359 and 512 days, respectively. Twenty of 29 patients (∼69%) on the megestrol acetate arm had stable disease lasting for a median duration of 117 days, whereas 21 of 29 patients (72%) on the dexamethasone arm had stable disease for a median duration of 86 days. Median survival of all patients was 9 months from initiation of treatment. The median survival for patients on the megestrol acetate arm was 268 days compared to 246 days for patients on the dexamethasone arm (P = 0.2). Neither dexamethasone nor megestrol acetate would seem to be of substantive value in altering the progression of advanced, hormonally refractory prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=0025150875&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025150875&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19900815)66:4<655::AID-CNCR2820660409>3.0.CO;2-P
DO - 10.1002/1097-0142(19900815)66:4<655::AID-CNCR2820660409>3.0.CO;2-P
M3 - Article
C2 - 2201425
AN - SCOPUS:0025150875
SN - 0008-543X
VL - 66
SP - 655
EP - 658
JO - Cancer
JF - Cancer
IS - 4
ER -